FindTrial
Sign In

Comparative efficacy of brigatinib and alectinib in ALK-rearrangement advanced non-small cell lung cancer with central nervous system metastasis: a network meta-analysis of phase3 randomized trials

Comparative efficacy of brigatinib and alectinib in ALK-rearrangement advanced non-small cell lung cancer with central nervous system metastasis: a network meta-analysis of phase3 randomized trials - brigatinib veusus alectinib in NSCLC

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000036861
Enrollment
500
Registered
2019-05-28
Start date
2019-05-12
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

None listed

Sponsors

Showa University School of Medicine, Department of Medicine, Division of Respiratory Medicine and Allergology,
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: phase3 studies of brigatinib or alectinib in patients with ALK positive advanced non-small cell lung cancer

Exclusion criteria

Exclusion criteria: Studies of patients with double cancer, immunecompromised patients, patients of poor performance status, and patients previously treated with ALT-TKIs

Design outcomes

Primary

MeasureTime frame
Progression free survival(PFS)—

Secondary

MeasureTime frame
Objective response rate(ORR)—

Countries

Japan

Contacts

Public ContactKoichi Ando

Showa University School of Medicine Department of Medicine, Division of Respiratory Medicine and Allergology,

koichi-a@med.showa-u.ac.jp03-3784-8000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026